Vaccine

BiondVax Reports Second Quarter Financial Results and Provides Business Update

JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on…

12 months ago

cbdMD Demonstrates Strong Year-over-Year Performance, Significantly Reducing Net Loss by $30 Million

Charlotte, North Carolina--(Newsfile Corp. - August 10, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the…

12 months ago

Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Water’s Commercial Products

CINCINNATI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical…

12 months ago

Inovalon Achieves NCQA HEDIS® Measure Certification for the 23rd Consecutive Year

Inovalon Converged Quality, Cloud Software Empowers More Than 80% of the Nation’s Clinical Outcomes Measurement AnalyticsBOWIE, Md., Aug. 10, 2023…

12 months ago

Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers

Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr.…

12 months ago

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the…

12 months ago

IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call…

12 months ago

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the…

12 months ago

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and…

12 months ago